For research and education only · Not reviewed by a medical professional · Disclaimer

Peptide encyclopedia/ Lanreotide
Illustration for Lanreotide

THE PEPSRADAR ENCYCLOPEDIA

Lanreotide

Somatostatin signaling in hormone-related conditions

Prescription medicines · Sources checked 2026-10-04

Read the studies ↓Explore the molecule ↗

Lanreotide · KEY FACTS

Content updated · how dates work

Saved peptides

Half-life source: FDA label (Lanreotide Acetate) on DailyMed ↗

What is Lanreotide?

Lanreotide is a prescription somatostatin analogue used in specific endocrine and neuroendocrine conditions. Its evidence depends on the disease being treated.

Biological role or research focus

Somatostatin signaling in hormone-related conditions.

Acromegaly, neuroendocrine tumors, and carcinoid syndrome are specific clinical contexts.

Role reference: MedlinePlus · Lanreotide ↗

Names you may encounter

Somatuline

Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.

Class / identity
Somatostatin analogue
Main research area
Hormonal suppression and selected tumors
Evidence featured
Human randomized trial
Source check
October 4, 2026

Source: MedlinePlus · Lanreotide ↗

Quick answers

Is Lanreotide FDA approved?
Yes. Somatuline Depot (NDA 022074, approved 2007) and lanreotide injection (NDA 215395) for acromegaly, gastroenteropancreatic neuroendocrine tumors and carcinoid syndrome. Source ↗
Is Lanreotide safe?
Approved somatostatin analog for acromegaly and certain hormone-producing tumors; gallstones, gut upset, blood sugar changes and a slower heart rate are the main concerns. Human safety data: its FDA label lists the known risks. The Risks & interactions section below lists what is known. Read the risks ↓
Is Lanreotide banned in sport?
It is not named on the 2026 World Anti-Doping Agency (WADA) Prohibited List. Athletes should still check with their sport’s anti-doping body. Source ↗

What does the evidence show?

Evidence map

Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.

1 Human research
StudyTypePopulation / model
CLARINET (2014)Human randomized trial204 patients with advanced, well/moderately differentiated, nonfunctioning, somatostatin-receptor-positive neuroendocrine tumors. Tumors were grade 1 or 2 with Ki-67 below 10%; 96% of participants had no progression in the preceding three to six months.

Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.

Human randomized trial · 2014

CLARINET

Lanreotide in metastatic enteropancreatic neuroendocrine tumors.

Population / model
204 patients with advanced, well/moderately differentiated, nonfunctioning, somatostatin-receptor-positive neuroendocrine tumors. Tumors were grade 1 or 2 with Ki-67 below 10%; 96% of participants had no progression in the preceding three to six months.
Study design
Lanreotide versus placebo for up to 96 weeks.
Main finding
Estimated progression-free survival at 24 months was 65.1% versus 33.0%; hazard ratio for progression or death 0.47. Overall survival and quality of life were not significantly different. The hazard ratio’s 95% CI was 0.30–0.73. Treatment-related diarrhea occurred in 26% versus 9%.
How to read it
The 24-month estimates differ by 32.1 percentage points. The hazard ratio concerns progression or death during follow-up; it is not a percentage of patients cured. Median progression-free survival was not reached in the lanreotide group versus 18 months with placebo.
Limits & context
The tumor subtype and receptor status are essential. Slowing progression is not the same as curing cancer, and cannot be generalized to unrelated tumors.

Source: Lanreotide in metastatic enteropancreatic neuroendocrine tumors. ↗

Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.

Registered human trials

81 registered studies name Lanreotide as an intervention among the 100 most recently updated of 119 search results; 6 are recruiting or under way, 0 have not started recruiting yet, 50 completed and 25 ended early, were withdrawn or have another status. Checked November 16, 2026 on ClinicalTrials.gov.

StudyStatusPhaseStartPeople
Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula
NCT06807437 · SWOG Cancer Research Network
RecruitingPhase 32025-05-09274
Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy
NCT05477576 · RayzeBio, Inc.
Active, not recruitingPhase 32022-03-24343
Randomized Interval Assessment Trial of Lu177-Dotatate in Slowly Progressive G1-2 Advanced Midgut Neuroendocrine Tumors
NCT06878664 · Grupo Espanol de Tumores Neuroendocrinos
RecruitingPhase 32025-06-12166
A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET
NCT05050942 · Camurus AB
Active, not recruitingPhase 32021-10-22332
Cabozantinib and Lanreotide as Treatment for Gastroenteropancreatic Neuroendocrine Tumors
NCT05048901 · National Health Research Institutes, Taiwan
RecruitingPhase 1 / Phase 22021-09-1749
Lanreotide In Polycystic Kidney Disease Study
NCT02127437 · Assistance Publique - Hôpitaux de Paris
CompletedPhase 32014-09-19159
LAnreotide in Metastatic Pheochromocytoma / PARAganglioma (LAMPARA)
NCT03946527 · Antonio Fojo
Active, not recruitingPhase 22019-06-1710
A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
NCT05364944 · Debiopharm International SA
TerminatedPhase 12022-05-1819

A registration shows a study was planned; it is not a result. Some studies use the compound only as a comparison or in a combination. All 81 listed studies.

Further reading · 4 additional publication links

Exact-name PubMed search checked 2026-10-04. These records have not been appraised. A name match can include related compounds, combinations, or other formulations; it does not establish safety or benefit.

Lanreotide. ↗
· 2012 · Review

Lanreotide autogel/depot in advanced enteropancreatic neuroendocrine tumours: final results of the CLARINET open-label extension study. ↗
Endocrine · 2021 Feb · Journal Article, Research Support, Non-U.S. Gov't
Read available full text ↗

Lanreotide. ↗
· 2006 · Review

Carcinoid Syndrome. ↗
· 2025 Jan · Study Guide

Repeat this PubMed search ↗
Search additional PubMed records ↗

Risks & interactions

Approved somatostatin analog for acromegaly and certain hormone-producing tumors; gallstones, gut upset, blood sugar changes and a slower heart rate are the main concerns.

Human safety data: FDA label

Safety comes from FDA-approved labeling (Somatuline Depot) based on trials in acromegaly, gastroenteropancreatic neuroendocrine tumors and carcinoid syndrome, plus postmarketing reports. Human pregnancy data are limited.

Take extra care with: Heart or blood pressure problemsDiabetes or blood-sugar medicines

From the FDA label lists below. If a condition applies to you, talk to a doctor or pharmacist first. Each tag opens every profile that mentions it.

Who should not use it

  • People with a past allergic reaction to lanreotide (including angioedema or anaphylaxis)

Interactions

  • Insulin and oral diabetes drugs: blood sugar may rise or fall, so treatment may need adjusting
  • Cyclosporine: lanreotide may reduce its absorption
  • Bromocriptine: lanreotide may increase its absorption
  • Beta-blockers and other heart-slowing drugs: added slowing of heart rate
  • Drugs cleared by liver CYP enzymes: their clearance may be reduced

Serious risks

  • Gallstones with complications such as gallbladder or bile duct inflammation and pancreatitis
  • High or low blood sugar
  • Slow heart rate (bradycardia)
  • Reduced thyroid function
  • Fatty stools and poor fat absorption from reduced pancreatic enzymes

Common side effects

  • diarrhea
  • abdominal pain
  • nausea
  • gallstones
  • injection-site reactions
  • vomiting
  • headache
  • musculoskeletal pain

Summarized from the FDA label with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: DailyMed: Somatuline Depot (lanreotide) prescribing information ↗

Key precautions

Blood-glucose changes, gallbladder problems, digestive effects, and heart-rate concerns warrant attention. Other endocrine disorders and interacting medicines affect monitoring.

Source: MedlinePlus · Lanreotide ↗

CLARINET-specific adverse-event context

Treatment-related diarrhea was the most common reported adverse event: 26% with lanreotide versus 9% with placebo. This trial-specific comparison does not summarize all product precautions or long-term harms.

Source: Lanreotide in metastatic enteropancreatic neuroendocrine tumors. ↗

Official product context · checked October 4, 2026

Medication information highlights blood-sugar changes and gallbladder, pancreatic, cardiac, and other medical-history considerations. The exact indication and preparation determine the monitoring framework.

Source: MedlinePlus · Lanreotide injection ↗

Regulatory status

U.S. FDA approval
Approved
Somatuline Depot (NDA 022074, approved 2007) and lanreotide injection (NDA 215395) for acromegaly, gastroenteropancreatic neuroendocrine tumors and carcinoid syndrome. source
FDA compounding (503A bulk list)
Not on FDA’s compounding lists
Not on FDA's 503A nominated-substance category lists. As a component of an FDA-approved drug it does not need to be on the 503A bulks list to be used in pharmacy compounding (other 503A conditions still apply). source
World Anti-Doping Agency (2026)
Not on the WADA Prohibited List
Not named and not within a prohibited class on the 2026 List. source

Checked October 28, 2026. Rules change; follow the source links for the current status. Regulatory tracker.

This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.

Medicine status & clinical context

Lanreotide is a prescription somatostatin agonist used in specified acromegaly, gastroenteropancreatic neuroendocrine tumor, and carcinoid-syndrome settings. Hormone-symptom control and tumor-progression outcomes are different clinical questions.

The medication reference covers acromegaly, certain gastrointestinal or pancreatic neuroendocrine tumors, and carcinoid syndrome. Symptom control and tumor-progression control are different clinical aims.

Source: MedlinePlus · Lanreotide injection ↗

New editorial updates

Loading approved updates…

New source discoveries

Links appear automatically. Unreviewed discoveries are not verified medical findings.

Loading recent discoveries…

Explore the latest source feed →

Sources & supplier listings

Why there are no prices here

This is a prescription medicine, available only with a prescription through a pharmacy. Versions sold online as "research" products are not the approved medicine, and the FDA has warned sellers of them, so PepsRadar does not list, compare or link them. See the official product information linked in References.

Mechanism & research rationale

It reduces secretion of selected hormones and related signaling. In neuroendocrine tumors, receptor expression and tumor characteristics help define the relevant research population.

Source: MedlinePlus · Lanreotide ↗

Molecular structure

Lanreotide: 2d molecular structure. The cited molecular record is shown. Salts, protonation, and formulation ingredients may differ from a specific product.⤢ Enlarge 2D
2D molecular structureThe cited molecular record is shown. Salts, protonation, and formulation ingredients may differ from a specific product.PubChem · CID 6918011 ↗

Questions worth asking

  • Which indication and formulation does the source describe?
  • Does the video make a broader claim than the source supports?
  • Acromegaly, neuroendocrine tumors, and carcinoid syndrome are specific clinical contexts.
  • What adverse effects, uncertainty, and conflicts of interest does the original source report?

Frequently asked questions

Does CLARINET apply to all cancers?

No. It enrolled a narrowly characterized group of neuroendocrine tumors.

Source: MedlinePlus · Lanreotide ↗

Is progression-free survival the same as overall survival?

No. The first measures time without progression or death; the second measures survival itself. CLARINET did not show a significant overall-survival difference.

Source: Lanreotide in metastatic enteropancreatic neuroendocrine tumors. ↗

Why do receptor status and tumor grade matter?

CLARINET required somatostatin-receptor-positive tumors with Ki-67 below 10%. The effect estimate should not be generalized to high-grade, receptor-negative, or unrelated cancers.

Source: Lanreotide in metastatic enteropancreatic neuroendocrine tumors. ↗

Does “median not reached” mean progression never occurred?

No. It means the estimated progression-free survival curve had not reached 50% at that analysis. It does not mean there were no events, and censoring and follow-up affect the estimate.

Source: Lanreotide in metastatic enteropancreatic neuroendocrine tumors. ↗

What remains uncertain from this abstract?

Overall survival and quality-of-life differences were not significant. Small subgroup estimates had wide confidence intervals, so the overall result does not establish the same effect in every subgroup.

Source: Lanreotide in metastatic enteropancreatic neuroendocrine tumors. ↗

How complete is this evidence review?

This profile summarizes selected NLM abstracts and linked medicine information. It is not a systematic review. Full-text verification and a comprehensive search have not been done, and this summary has not been reviewed by a medical professional.

Does the official medicine reference cover every use discussed online?

No. The reference covers defined products and clinical settings. Research outside those uses needs separate evidence and does not extend the medicine’s authorization.

Source: MedlinePlus · Lanreotide injection ↗

References & editorial record

Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation.

For research and education only. This page does not provide medical advice, diagnosis, or treatment. Research-only listings are not instructions for human use.

See something wrong on this page? Report a mistake · Corrections

MOLECULAR ATLAS

Lanreotide

Download illustration ↓Source record ↗
Lanreotide 2d molecular structure

The cited molecular record is shown. Salts, protonation, and formulation ingredients may differ from a specific product.